Across TCGA pan-cancer cohorts, RAB12 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RAB12 data layer compared with 22 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher RAB12 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RAB12 expression acts as an unfavorable survival marker.

SARC, UCEC, and LUSC are the cancer types where RAB12 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	OS	Median	All	0.210	0.745	.014	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUSC	OS	Median	All	0.138	0.818	.003	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: RAB12 tumor-vs-normal RNA expression · all RAB12 data types